领航医药生物科技(00399)上涨6.15%，报0.69元/股

Group 1 - The core business of the company includes the research and development of pharmaceutical products and the trade of beauty instruments and products, with a particular focus on oral insulin products [1] - As of July 30, the company's stock price increased by 6.15%, reaching HKD 0.69 per share, with a trading volume of HKD 9.672 million [1] - For the fiscal year ending 2024, the company reported total revenue of HKD 1.9296 million and a net loss of HKD 319 million [2]